Patient Preference and Adherence · 2021 · 15 citations · 24 references
PharmacyPharmacoeconomicsPharmacotherapyCost-effectiveness AnalysisCost-utility AnalysisPharmacoeconomic ModelingNeurodegenerative Disease PharmacotherapyParkinson DiseasePatient PreferencesWillingness-to-pay ThresholdsDiscrete Choice Experiment DesignDiscrete Choice ModellingEliciting Patient PreferencesMedication Preference AssessmentOn-demand TreatmentOut-of-pocket Cost ReductionTreatment Attribute PreferencesTreatment Choice Preferences
INTRODUCTION: Several on-demand treatments are available for management of "OFF" episodes in patients with Parkinson's disease (PD). We evaluated patients' preferences for features of theoretical on-demand treatment options. METHODS: In a discrete choice experiment, US adults with self-reported PD of ≥5 years, or <5 years with "OFF" episodes, taking oral carbidopa/levodopa, selected between pairs of theoretical on-demand treatments that varied by mode of administration (with and without mode-specific adverse events [AEs]), time to FULL "ON," duration of "ON," and out-of-pocket cost for a 30-day supply. Data were analyzed with a random parameters logit model; results were used to calculate relative importance of treatment attributes, preference shares, and willingness to pay. RESULTS: Among 300 respondents, 98% had "OFF" episodes. Across the range of attribute levels included in the survey, avoiding $90 cost was most important to respondents, followed by a preferable mode of administration with associated AEs and decreasing time to FULL "ON." Duration of "ON" was relatively less important. On average, respondents preferred a theoretical dissolvable sublingual film versus other theoretical treatments with alternative modes of administration. Respondents were willing to pay $28-$52 US dollars to switch from least- to more-preferred mode of administration with associated AEs, $58 to reach FULL "ON" in 15 versus 60 min, and $9 to increase duration of FULL "ON" from 1 to 2 h. CONCLUSION: Respondents with PD valued lower out-of-pocket cost and a sublingual mode of administration with its associated AEs when choosing an on-demand treatment for "OFF" episodes.
24
F. Reed Johnson, Emily Lancsar, Deborah A. Marshall et al. · Value in Health · 2013 · 1.8K citations
Brett Hauber, Juan Marcos González, Karin Groothuis‐Oudshoorn et al. · Value in Health · 2016 · 1.3K citations · Full text
Prevalence of Parkinson’s disease across North America
Connie Marras, James C. Beck, James H. Bower et al. · npj Parkinson s Disease · 2018 · 1K citations · Full text
Olivier Rascol, E. Melamed, Wolfgang H. Oertel et al. · The Lancet · 2005 · 634 citations · Full text